San Diego-based Viking Therapeutics marked itself as a significant competitor in the weight loss drug market in February immediately after revealing promising data from the mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied being a weekly injection and in March the compan